Vaxcyte, Inc.

Equities

PCVX

US92243G1085

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 07:27:37 18/09/2024 pm IST			5-day change	1st Jan Change
116.26 ^USD	-0.42%		+2.56%	+85.44%

10/09	Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...
10/09	Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	MT

Vaxcyte, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024

May 09, 2024 at 01:35 am IST

Vaxcyte, Inc. reported earnings results for the first quarter ended March 31, 2024. For the first quarter, the company reported net loss was USD 95.02 million compared to USD 60.46 million a year ago. Basic loss per share from continuing operations was USD 0.85 compared to USD 0.7 a year ago.

Latest news about Vaxcyte, Inc.

Analyst recommendations: Apple, Oracle, Progressive, Dollar Tree...	10/09
Mizuho Boosts Price Target on Vaxcyte to $163 From $113, Maintains Outperform Rating	10/09	MT
Health Care Helped By Defensive Bias - Health Care Roundup	07/09	DJ
Vaxcyte Closes $1.5 Billion Offering of Shares, Warrants	07/09	MT
Vaxcyte Prices $1.3 Billion Offering of Shares, Warrants	05/09	MT
Health Care Losses Limited By Vaxcyte's Surge - Health Care Roundup	04/09	DJ
Vaxcyte Starts $1 Billion Underwritten Public Offering	04/09	MT
Sector Update: Health Care Stocks Decline Late Afternoon	04/09	MT
Sector Update: Health Care Stocks Retreat in Afternoon Trading	03/09	MT
Sector Update: Health Care	03/09	MT
Vaxcyte Shares Rise After Plans for Phase 3 Trial of 31-Valent Pneumococcal Conjugate Vaccine Candidate	03/09	MT
Vaxcyte's shares hit record high on early data on pneumococcal vaccine	03/09	RE
Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday	03/09	MT
Wall Street Set to Open Shortened Week Lower Tuesday as Investors Await Manufacturing Data	03/09	MT
Sector Update: Health Care	03/09	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Key Jobs Report	03/09	MT
Vaxcyte Plans Phase 3 Trial for 31-Valent Pneumococcal Conjugate Vaccine Candidate After 'Positive' Phase 1/2 Study Results	03/09	MT
September Kicks Off With US Futures Moving Lower Ahead of Manufacturing Data	03/09	MT
Transcript : Vaxcyte, Inc. - Special Call	03/09
Vaxcyte Reports Positive Topline Data from Phase 1/2 Study of VAX-31, its 31-Valent Pneumococcal Conjugate Vaccine Candidate, in Adults Aged 50 and Older	03/09	CI
Vaxcyte Insider Sold Shares Worth $1,184,767, According to a Recent SEC Filing	27/08	MT
Vaxcyte, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	07/08	CI
Vaxcyte Insider Sold Shares Worth $1,263,912, According to a Recent SEC Filing	25/07	MT
Vaxcyte Insider Sold Shares Worth $649,325, According to a Recent SEC Filing	23/07	MT
Vaxcyte Insider Sold Shares Worth $425,000, According to a Recent SEC Filing	18/07	MT

Chart Vaxcyte, Inc.

Duration

Period

More charts

Company Profile

Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Companyâs next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Employees

254

Sector

Biotechnology & Medical Research

Calendar

07:50pm - Cantor Global Healthcare Conference

More about the company